As part of its strategic transformation, Ind-Swift Group undertook significant structural realignment to strengthen its formulation-focused business model. In 2024, the Group transferred its API and CRAMS businesses to Synthimed Pvt. Ltd., a part of the India Resurgence Fund group, enabling a sharper focus on formulation-led growth and enhanced operational clarity. Subsequently, the amalgamation of Ind-Swift Limited into Ind-Swift Laboratories Limited, completed in August 2025, marked a key milestone in consolidating pharmaceutical capabilities under a single entity. This strategic move was aimed at optimizing operations, improving cost efficiencies, and creating a more agile, integrated organization aligned with long-term growth and governance objectives.